Mouse Genome Informatics
cn1
    Jak2tm1(JAK2)Argr/Jak2+
Tg(Mx1-cre)1Cgn/0

involves: 129S7/SvEvBrd * C57BL/6 * CBA
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
hematopoietic system
• at 6 and 26 weeks following pIpC administration, the number of pro-erythrocytes and terminally differentiated erythroblasts is increased compared to in wild-type mice
• in 10% of mice following pIpC administration
• in 10% of mice following pIpC administration
• following pIpC administration
• in one mouse following pIpC administration
• following pIpC administration
• in one mouse following pIpC administration
• following pIpC administration,10% of mice exhibit increase in Ter119+ erythroid cells in bone marrow (BM), CD71+Ter119+ erythroid cells in the spleen, and Mac1+Gr1+ cells in BM and spleen compared with wild-type mice
• following pIpC administration, one mouse exhibited granulocytic hyperplasia, patchy accumulation of immature cells, reduction of erythroid and megakaryocytic cells, development of collagen fibrosis, decreased Ter119+ erythroid cells in BM, increased CD71+Ter119+ erythroid cells in the spleen, and increased Mac1+Gr1+ cells in BM and spleen compared with wild-type mice
• 26 weeks following pIpC administration, the number of Gr+Mac1+ cells is modestly increased compared to in wild-type mice
• 10 weeks after pIpC treatment, bone marrow cells exposed to thrombopoietin (TPO) exhibit increased number of ploidy CD41+ cells compared with similarly treated wild-type cells
• 6 weeks, but not 26 weeks, after pIpC treatment, mice exhibit increased bone marrow-derived colony-forming units-granulocyte, colony-forming units-macrophage, and colony forming units granulocyte-macrophage (CFU-GM) compared with wild-type mice
• however, no TPO-independent megakaryocyte colonies are observed
• modestly at 6 weeks after pIpC treatment in the presence or absence of erythropoietin (EPO)
• significant at 26 weeks after pIpC and EPO treatment with an increase in EPO-independent BFU-E at 26 weeks
• following pIpC administration
• at 6 and 26 weeks following pIpC administration, mice exhibit megakaryocytic hyperplasia with large and hyperlobated forms unlike in wild-type mice
• after pIpC treatment, mice exhibit reduced numbers of LSK cells compared with wild-type mice
• in 10% of mice following pIpC administration
• after pIpC treatment, LSK cells exhibit increased DNA damage, reduced cell cycling, and reduced apoptosis compared with wild-type mice
• in transplantation assays, hematopoietic stem cells from pIpC treated mice exhibits impaired long-term repopulation compared with wild-type cells

immune system
• in one mouse following pIpC administration
• following pIpC administration
• in 10% of mice following pIpC administration

skeleton
• following pIpC administration,10% of mice exhibit bone marrow fibrosis unlike wild-type mice

cellular
• 26 weeks following pIpC administration, the number of Gr+Mac1+ cells is modestly increased compared to in wild-type mice
• 10 weeks after pIpC treatment, bone marrow cells exposed to thrombopoietin (TPO) exhibit increased number of ploidy CD41+ cells compared with similarly treated wild-type cells

Mouse Models of Human Disease
OMIM IDRef(s)
Thrombocythemia 1; THCYT1 187950 J:164539